CYPRESS BIOPHARMA, INC.

Biotech · Private

Small-molecule nuclear receptor agonist (CBP-002) targeting kidney podocytes for nephrotic syndrome treatment

Grants
$306K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Leveraging the Highly Active Metabolite of Pioglitazone as a Scaffold for a Novel Non-Immunosuppressive Therapy for Childhood Nephrotic Syndrome.$305,786
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2876LIBREDE——
2877DELINEATE INC——
2878SPECTRAL THERAPEUTICS, INC.——
2879CYPRESS BIOPHARMA, INC.——
2880Sophia Bioscience Inc——
2881CG Oncology——
2882LABORECOM THERAPEUTICS INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.